对不确定期慢性HBV感染者应否抗病毒治疗的思考

刘志华

doi:10.3969/j.issn.1001-5256.2021.12.009

对不确定期慢性HBV感染者应否抗病毒治疗的思考

DOI: 10.3969/j.issn.1001-5256.2021.12.009

刘志华^,

南方医科大学南方医院感染科，广州 510515

详细信息

通信作者:
刘志华，zhihualiu@126.com

中图分类号: R512.62
计量
- 文章访问数: 303
- HTML全文浏览量: 77
- PDF下载量: 82
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-27
- 录用日期: 2021-09-27
- 出版日期: 2021-12-20

Thoughts on whether patients in the indeterminate phase of chronic hepatitis B virus infection should receive antiviral therapy

Zhihua LIU^,

Department of Infectious Diseases, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎, 慢性 /
- 不确定期 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Indeterminate phrase /
- Therapeutic

HTML全文

参考文献(12)

[1]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[2]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[3]	TERRAULT NA, LOK A, McMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[4]	SPRADLING PR, XING J, RUPP LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013[J]. Aliment Pharmacol Ther, 2016, 44(10): 1080-1089. DOI: 10.1111/apt.13802.
[5]	HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019. [Online ahead of print]
[6]	JIA J, HOU J, DING H, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2015, 30(4): 756-762. DOI: 10.1111/jgh.12840.
[7]	KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64(4): 773-780. DOI: 10.1016/j.jhep.2015.11.012.
[8]	WAI CT, CHENG CL, WEE A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B[J]. Liver Int, 2006, 26(6): 666-672. DOI: 10.1111/j.1478-3231.2006.01287.x.
[9]	YANG HI, YUEN MF, CHAN HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score[J]. Lancet Oncol, 2011, 12(6): 568-574. DOI: 10.1016/S1470-2045(11)70077-8.
[10]	FAN C, LI M, GAN Y, et al. A simple AGED score for risk classification of primary liver cancer: Development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China[J]. Gut, 2019, 68(5): 948-949. DOI: 10.1136/gutjnl-2018-316525.
[11]	FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6): 1368-1378. DOI: 10.1016/j.jhep.2020.07.025.
[12]	World Health Organization. WHO global health sector strategy on viral hepatitis 2016-2021: Towards ending viral hepatitis[EB/OL]. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1.